INS and type 2 diabetes mellitus: In a retrospective study that assessed a propensity score-matched cohort of insulin pump and MDI users, Gill et al. investigated the differences in health care resource utilization and costs between individuals with T1D and T2D treated with insulin pump or MDI therapy who met or did not meet the Medicare C-peptide/beta cell antibody eligibility criteria.56 For these comparisons, investigators structured the study as three analyses.